jump to navigation

Treating Obese is very expensive July 27, 2009

Posted by healthandsurvival in Diseases, Obese.
Tags: , , , , ,
1 comment so far

By BETSY MCKAY

The medical costs of treating obesity-related diseases may have soared as high as $147 billion in 2008, the Centers for Disease Control and Prevention said Monday, as its new director set a fresh tone in favor of more aggressively attacking obesity.

The cost of treating obesity doubled over a decade, signaling the rising prevalence of excess weight and the toll it is taking on the health-care system. The medical costs of obesity were estimated to be $74 billion in 1998, according to a study by federal government researchers and RTI International, a nonprofit research institute in Research Triangle Park, N.C.

The findings were released at a conference on obesity held by the CDC in Washington, D.C. The prevalence of obesity rose 37% between 1998 and 2006, and medical costs climbed to about 9.1% of all U.S. medical costs, the researchers said.

Obese people spent 42% more than people of normal weight on medical costs in 2006, a difference of $1,429, the study found. Prescription drugs accounted for much of the increase.

The numbers underscore the urgent need for deeper interventions in society and the environment that will make it easier for people to maintain normal weight, Thomas Frieden, the CDC’s new director, told conference attendees. While obesity rates among some population groups have shown signs of leveling off, that is of little comfort, he said: The average American is about 23 pounds overweight. Obesity is causing disabilities and exacerbating health disparities, he said. The average American consumes about 250 calories more a day now than two or three decades ago.

“Obesity and with it diabetes are the only major health problems that are getting worse in this country, and they’re getting worse rapidly,” he said.

Change is needed on many fronts, he added. “Reversing obesity is not going to be done successfully with individual effort.”

While the CDC is not a regulatory agency and has only a $43 million budget this year for nutrition, physical activity and obesity programs, it is now stepping up its efforts to combat obesity. Last week, the agency released a set of recommendations to help communities prevent and combat obesity. They include discouraging the consumption of sugar-sweetened beverages, instituting smaller portion-size options in venues such as government facilities, and requiring physical education in schools.

As New York City’s health commissioner for more than seven years, Dr. Frieden was known for measures such as banning artificial trans fats in some foods and requiring certain chain restaurants to post calorie counts on their menus. In an article published in April in the New England Journal of Medicine, Dr. Frieden and Kelly Brownell, a professor at Yale University, proposed a penny-an-ounce tax on sugar-sweetened beverages, arguing that those drinks “may be the single largest driver of the obesity epidemic.”

In his speech Monday, Dr. Frieden—who became CDC director in June—said measures that had worked to control tobacco, such as taxes and reducing exposure, could help control obesity, too. Those could include a tax on sugar-sweetened beverages. A 10% price increase on sugared beverages could reduce consumption 7.8%, he said.

But he didn’t express the proposal as a policy of the Obama administration. The CDC doesn’t officially endorse an increase in taxes on soda, but cites price increases as a proven strategy for tobacco control and says they should be considered as a strategy for obesity control.

The beverage industry opposes soda-tax proposals. “It’s overreaching when government uses the tax code to tell people what they can eat or drink, said Kevin Keane, a spokesman for the American Beverage Association. “It’s hard to make the connection that there’s a unique tie between soft drinks and obesity.”

Wein Fitseal Mask and Wein Viraseal N99 mask July 26, 2009

Posted by healthandsurvival in Infectious Disease.
Tags: , , , , ,
add a comment

Wein Products, manufacturer of the Viramask and Fitseal. A great tool to help minimize risk of infection with H1N1 (swine) flu or  avian influenza.  Watch the video below to learn more about how it works.  To purchase, visit www.eHealthSupplies.com  , a certified Wein Products Distributor.

Exercise better than heart surgery July 11, 2009

Posted by healthandsurvival in health.
Tags: , , , , , , ,
1 comment so far

Studies have shown that exercise is better than heart surgery, or angioplasty.

———–

(NaturalNews) At the European Association of Cardiovascular Prevention and Rehabilitation meeting recently held in Barcelona, Spain, new heart research was presented that shows one treatment in particular can provide remarkable help for patients with certain forms of serious heart disease. It’s not a new drug or surgical procedure. Instead, it’s a natural therapy — plain old-fashioned regular exercise.

In fact, in several studies just presented at the meeting, exercise reduced the markers of heart disease in patients following coronary artery bypass surgery (CABG). What’s more, it improved indications of disease in people with heart failure, a condition usually thought to be incurable and often just treated with symptom-relieving drugs. But the news that’s perhaps most likely to make some interventional cardiologists’ hearts skip a beat or two was the evidence presented that showed that exercise improved cardiac event-free survival in coronary patients better than angioplasty with stents.

Also called percutaneous coronary intervention (PCI), angioplasty is commonly used to help people with coronary artery disease whose arteries are narrowed and even blocked by a build-up of sticky plaque. By threading a thin tube through a blood vessel in the arm or groin, interventional cardiologists perform angioplasty to restore blood flood through a clogged artery. A tiny balloon at the end of the tube is inflated when it reaches the exact spot of blockage. That pushes the plaque outward against the walls of the artery, restoring blood flow. A small metal device called a stent is also carried by the tube and deployed at the site of the blockage in order to prop open the artery.

This approach to treating heart disease is a huge business. A report in Bloomberg News last fall noted that about 800,000 angioplasties are performed each year in the U.S. at a cost of about $10 billion annually. And, although many cardiologists consider angioplasty to be the “gold standard” of care in most types of acute coronary events such as heart attack, the procedure’s long term benefits have been questioned by many doctors. In addition, the role of angioplasty in treating other kinds of coronary disease, like angina, isn’t clear....read more here…

Angioplasty Does Not Extend Life… July 11, 2009

Posted by healthandsurvival in health.
Tags: , , ,
add a comment

Heart Drugs More Cost-Effective Than Angioplasty, Study Finds

By Alex Nussbaum

Sept. 24 (Bloomberg) — Artery-opening angioplasty adds $10,125 to a patient’s medical bill without significantly extending life or improving health for someone with chest pain, researchers said.

The figure, released today by the American Heart Association, is the latest finding that prompts some doctors to question the value of angioplasty procedures performed on more than 800,000 U.S. patients each year, at a cost of about $10 billion annually. Half of those are done to treat “stable” angina — temporary chest pains that can be treated with drugs, diet changes and exercise, the study said.

The procedure, in which a heart artery is unclogged with a balloon and propped open with a tiny tube called a stent, costs $34,843, including follow-up care. That compares with $24,718 for a regimen of anti-cholesterol medicines and lifestyle changes, researchers reported in the association’s journal, Circulation: Cardiovascular Quality and Outcomes.

“Although the difference narrows somewhat over time, it is never made up,” the researchers said in the study. While angioplasties may make sense for heart attack or severe blockages, “medical therapy alone offered better outcome at a lower cost” for those with stable coronary disease.

The results pose a challenge for device makers including Boston Scientific Corp., Abbott Laboratories,Johnson & Johnson and Medtronic Inc., whose revenue from drug-coated stents topped $4 billion in 2007. Sales of the $2,000 tubes have rebounded after falling 30 percent last year amid concerns the products triggered fatal blood clots.

Seven-Year Study

The study, funded by the U.S. and Canadian governments, is the third installment of a seven-year investigation dubbed Courage. Last year, researchers said drugs and lifestyle changes prevented deaths and heart attacks just as well as angioplasty. A report last month found both methods effective at easing chest pains after two years, though angioplasty offered some early advantages.

Most of the increased expense of angioplasty came from the operation itself, which cost $12,162 compared with $752 for the initial drug therapy. After that, follow-up care and medication expenses were about the same.

Angioplasties increased costs by $206,229 per year of extended life, said the researchers, led by William Weintraub, a cardiologist at Christiana Health Care System of Newark, Delaware….read more here…

Darvocet Warning Released by FDA July 7, 2009

Posted by healthandsurvival in Drugs, medicine.
Tags: , , , ,
2 comments

July 7, 2009 — The US Food and Drug Administration (FDA) is adding stronger warnings to pain medications that contain propoxyphene, such as Darvon and Darvocet, because of new data on fatal overdoses linked to propoxyphene products. The FDA is requiring the manufacturers of these drugs to strengthen the drug’s boxed warning and to create a medication guide for patients.

The agency is stopping short of a phased withdrawal from the market as demanded by a Public Citizen petition filed in 2006.

To reduce the likelihood of overdose, the FDA will now require that manufacturers of propoxyphene-containing medications strengthen their label and include a boxed warning on the potential for overdose. Manufacturers will also be required to develop a medication guide for patients stressing that they use the medication as directed. Propoxyphene has been on the market since 1957.

Between 1969 and 2005, an FDA database has linked a total of 91 deaths in persons taking propoxyphene related to accidental overdoses and suicide attempts, although a direct link to propoxyphene is difficult to establish because multiple drugs and other conditions were involved, the agency said.

The FDA is currently working with several organizations, including the Centers for Medicare & Medicaid Services and the Veterans Health Administration, to collect data for a new safety study that will assess the cardiotoxic effects of propoxyphene at higher doses, particularly in elderly populations; findings from this study could lead to additional regulatory action. At this time, the FDA is looking at how Americans are using medications containing propoxyphene, and in which combinations.

Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research, told reporters during a press briefing that propoxyphene is an accepted option for pain treatment at this time. “Pain is an important issue — it’s the fifth vital sign. Millions of people suffer from pain; it is so prevalent that 1 in 10 people have chronic pain, and the FDA is committed to appropriate treatment of pain. At this time, propoxyphene is an acceptable choice for the treatment of mild to moderate pain when taken as directed.”

Dr. Woodcock noted that after last week’s advisory meeting on acetaminophen safety, the FDA heard from hundreds of patients concerned about the availability of their medications that contain acetaminophen.

“When it comes to acetaminophen or opioids, the FDA is constantly balancing benefit vs risk,” she said.

The FDA said that in cases of overdose, propoxyphene can be a fatal medicine; however, most of the deaths connected to the drug in the FDA’s database were in cases of ingestion of multiple drugs.

The consumer group Public Citizen petitioned the FDA in February 2006, asking that propoxyphene-containing products, sold primarily as a generic drug, be removed from the market. The FDA declined today to take action on the petition. The drug was withdrawn from the UK market in 2005, however, when the British government said it was unimpressed with the efficacy of the drug and that the risk of toxicity in cases of overdose — both intentional and accidental — were unacceptable.

The FDA defended its position in not removing the drug from the market, pointing out that there are not a lot of alternative drugs without similar adverse effects...read more here..